Business
Crescent Biopharma is a clinical-stage oncology company built around CR-001, a PD-1 x VEGF bispecific antibody, and an antibody drug conjugate portfolio.
Crescent Biopharma reset into oncology in FY2025, but the company had a $153.9M loss and $72.5M of negative FCF.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage oncologyNote
- Revenue — $10.8MNote
- Net income — ($153.9M)Watch
- FCF — ($72.5M)Watch
- Equity — $203.0M, from deficitOK
- Insiders — $18.24M purchase and 0 salesOK
- Accounting — Altman weak; other screens unavailableWatch
Where the revenue comes from
Fiscal 2025, as CRESCENT BIOPHARMA, INC. reports it. History and quarterly detail are in the app.
- Reportable$10.8M
Leadership changes
From CRESCENT BIOPHARMA, INC.'s own filings, the day they're filed.
- Mark Goldberg · Directors · departureeff. 2025-02-21
- Rachel King · Directors · departureeff. 2025-02-21
- Scott Koenig · Directors · departureeff. 2025-02-21
Latest filings
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-07-15
- 8-K · Company announcement2026-07-14
- 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CRESCENT BIOPHARMA, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.